Oncternal Therapeutics, Inc. Common Stock
ONCT
ONCT was delisted on the 2nd of December, 2024.
34 hedge funds and large institutions have $8.41M invested in Oncternal Therapeutics, Inc. Common Stock in 2016 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, 6 reducing their positions, and 5 closing their positions.
12% more capital invested
Capital invested by funds: $7.51M → $8.41M (+$895K)
6% less funds holding
Funds holding: 36 → 34 (-2)
40% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 5
50% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$22.4K |
| 2 |
IA
IFP Advisors
Tampa,
Florida
|
+$8.41K |
| 3 |
DAM
Delta Asset Management
Memphis,
Tennessee
|
+$7.48K |
| 4 |
VKH
Virtu KCG Holdings
New York
|
+$7.48K |
| 5 |
Creative Planning
Overland Park,
Kansas
|
+$3.74K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Group One Trading
Chicago,
Illinois
|
-$28K |
| 2 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
-$17.8K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$11K |
| 4 |
DT
Diversified Trust
Memphis,
Tennessee
|
-$9.35K |
| 5 |
LPL Financial
San Diego,
California
|
-$9K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
| $4K | – | – | – |
|
27
UBS Group
Zurich,
Switzerland
| $4K | – | – | – |
|
|
28
Creative Planning
Overland Park,
Kansas
| $4K | +$3.74K | +4 | +400% |
|
29
Citigroup
New York
| $3K | – | – | – |
|
|
JIR
30
James Investment Research
Alpha,
Ohio
| $3K | – | – | – |
|
|
TDC
31
Thompson Davis & Co
Richmond,
Virginia
| $3K | – | – | – |
|
32
Wells Fargo
San Francisco,
California
| $2K | -$3.74K | -4 | -57% |
|
33
Morgan Stanley
New York
| $2K | -$935 | -1 | -25% |
|
|
34
Group One Trading
Chicago,
Illinois
| – | -$28K | -30 | Closed |
|
|
35
Citadel Advisors
Miami,
Florida
| – | -$11K | -15 | Closed |
|
|
36
LPL Financial
San Diego,
California
| – | -$9K | -11 | Closed |
|
|
BIM
37
BlackRock Investment Management
Wilmington,
Delaware
| – | -$6K | -9 | Closed |
|
|
AIG
38
American International Group
New York
| – | -$1K | -1 | Closed |
|
|
AG
39
Advisor Group
Phoenix,
Arizona
| – | +$935 | +1 | New |
|
ONCT Hedge Fund Activity: Q2 2016 in Review
34 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in Oncternal Therapeutics, Inc. Common Stock (ONCT) for Q2 2016, worth a combined $8.41M — up 12% from $7.51M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of ONCT and 3 opened new positions — a net loss of 2 holders — while 6 trimmed existing stakes and 3 added.
The largest buyer was Goldman Sachs, adding an estimated $22.4K. The largest seller was Group One Trading, exiting entirely with an estimated $28K sold.
- 34 institutional investors held Oncternal Therapeutics, Inc. Common Stock (ONCT) as of Q2 2016, down from 36 in Q1 2016.
- Funds reported $8.41M of Oncternal Therapeutics, Inc. Common Stock stock for Q2 2016, up 12% quarter-over-quarter.
- 3 funds opened new Oncternal Therapeutics, Inc. Common Stock positions in Q2 2016 and 5 closed out, a net change of -2 holders.
- The largest Oncternal Therapeutics, Inc. Common Stock buyer in Q2 2016 was Goldman Sachs, an estimated $22.4K added.
- The largest Oncternal Therapeutics, Inc. Common Stock seller in Q2 2016 was Group One Trading, an estimated $28K sold.
Based on aggregated 13F filings for Q2 2016.